The Boston Business Journal first reported that Ensemble Therapeutics has shut its doors for good. Focused on developing small molecule therapies for cancer and other disease, Ensemble Therapeutics quietly closed up shop after 13 years.
Two Roche drugs were placed on partial clinical hold as the U.S. FDA continues to examine potential dangers of checkpoint inhibitors following deaths associated with Merck’s Keytruda.
Six months after losing its CEO, Galena Biopharma was absorbed in a reverse merger with Sellas Life Sciences to form a new company, Sellas Life Science Group Inc. The newly merged companies will focus on developing novel treatments for cancer.
Biopharmaceutical company Celgene Corp. will buy a stake in BeiGene Ltd. and help develop and commercialize BeiGene’s investigational treatment for tumor cancers.
Checkpoint inhibitors have become popular treatments for cancers, but a New England Journal of Medicine article may give physicians pause before prescribing them.
Sorrento Therapeutics and Servier have inked a license and collaboration deal to develop, manufacture and commercialize products using Sorrento’s STI-A1110.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
FDA gave Tecentriq accelerated approval to treat specific types of advanced bladder cancer.
BioSpace (DHX) is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the […]
